{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:53:43Z","timestamp":1773687223808,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Semant"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13326-015-0017-1","type":"journal-article","created":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T23:33:26Z","timestamp":1428708806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Exploring adverse drug events at the class level"],"prefix":"10.1186","volume":"6","author":[{"given":"Rainer","family":"Winnenburg","sequence":"first","affiliation":[]},{"given":"Alfred","family":"Sorbello","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Bodenreider","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,5,1]]},"reference":[{"key":"17_CR1","unstructured":"Reducing and Preventing Adverse Drug Events To Decrease Hospital Costs [http:\/\/www.ahrq.gov\/research\/findings\/factsheets\/errors-safety\/aderia\/index.html]"},{"key":"17_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1745-6215-13-138","volume":"13","author":"S Singh","year":"2012","unstructured":"Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012;13:138.","journal-title":"Trials"},{"key":"17_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796\u2013803.","journal-title":"Int J Med Sci"},{"key":"17_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/amiajnl-2013-001612","volume":"21","author":"SV Iyer","year":"2014","unstructured":"Iyer SV, Harpaz R, LePendu P, Bauer-Mehren A, Shah NH. Mining clinical text for signals of adverse drug-drug interactions. J Am Med Inform Assoc. 2014;21:353\u201362.","journal-title":"J Am Med Inform Assoc"},{"key":"17_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/amiajnl-2012-001083","volume":"20","author":"P Avillach","year":"2013","unstructured":"Avillach P, Dufour JC, Diallo G, Salvo F, Joubert M, Thiessard F, et al. Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project. J Am Med Inform Assoc. 2013;20:446\u201352.","journal-title":"J Am Med Inform Assoc"},{"key":"17_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2165\/00148581-200709030-00008","volume":"9","author":"K Schror","year":"2007","unstructured":"Schror K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs. 2007;9:195\u2013204.","journal-title":"Paediatr Drugs"},{"key":"17_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tox.2008.04.015","volume":"249","author":"OW Guthrie","year":"2008","unstructured":"Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology. 2008;249:91\u20136.","journal-title":"Toxicology"},{"key":"17_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/157488609789006949","volume":"4","author":"J Beltowski","year":"2009","unstructured":"Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf. 2009;4:209\u201328.","journal-title":"Curr Drug Saf"},{"key":"17_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2165\/00002018-200932040-00005","volume":"32","author":"P Haber","year":"2009","unstructured":"Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and guillain-barre syndrome. Drug Saf. 2009;32:309\u201323.","journal-title":"Drug Saf"},{"key":"17_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.blre.2013.02.004","volume":"27","author":"LA Linkins","year":"2013","unstructured":"Linkins LA. Bleeding risks associated with vitamin K antagonists. Blood Rev. 2013;27:111\u20138.","journal-title":"Blood Rev"},{"key":"17_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40264-013-0089-8","volume":"36","author":"AL Stephenson","year":"2013","unstructured":"Stephenson AL, Wu W, Cortes D, Rochon PA. Tendon Injury and Fluoroquinolone Use: A Systematic Review. Drug Saf. 2013;36:709\u201321.","journal-title":"Drug Saf"},{"key":"17_CR12","unstructured":"Medical Subjects Headings (MeSH) [http:\/\/www.nlm.nih.gov\/mesh\/]"},{"key":"17_CR13","unstructured":"ATC\/DDD Index [http:\/\/www.whocc.no\/atc_ddd_index\/]"},{"key":"17_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","volume":"18","author":"SJ Nelson","year":"2011","unstructured":"Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6\u00a0years. J Am Med Inform Assoc. 2011;18:441\u20138.","journal-title":"J Am Med Inform Assoc"},{"key":"17_CR15","unstructured":"RxNorm API [http:\/\/rxnav.nlm.nih.gov\/]"},{"key":"17_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/msb.2009.98","volume":"6","author":"M Kuhn","year":"2010","unstructured":"Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol. 2010;6:343.","journal-title":"Mol Syst Biol"},{"key":"17_CR17","first-page":"100","volume":"2013","author":"G Jiang","year":"2013","unstructured":"Jiang G, Liu H, Solbrig HR, Chute CG. ADEpedia 2.0: integration of normalized adverse drug events (ADEs) knowledge from the UMLS. AMIA Jt Summits Transl Sci Proc. 2013;2013:100\u20134.","journal-title":"AMIA Jt Summits Transl Sci Proc"},{"key":"17_CR18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1021\/ci4000079","volume":"53","author":"F Cheng","year":"2013","unstructured":"Cheng F, Li W, Wang X, Zhou Y, Wu Z, Shen J, et al. Adverse drug events: database construction and in silico prediction. J Chem Inf Model. 2013;53:744\u201352.","journal-title":"J Chem Inf Model"},{"key":"17_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/HRP.0000000000000039","volume":"22","author":"M Siamouli","year":"2014","unstructured":"Siamouli M, Samara M, Fountoulakis KN. Is antiepileptic-induced suicidality a data-based class effect or an exaggeration? A comment on the literature. Harv Rev Psychiatry. 2014;22:379\u201381.","journal-title":"Harv Rev Psychiatry"},{"key":"17_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2515\/therapie\/2014063","volume":"69","author":"C Khouri","year":"2014","unstructured":"Khouri C, Jean Bart E, Logerot S, Decker-Bellaton A, Bontemps H, Mallaret M. [Dysthyroidism with anti-VEGF treatment, a class effect? about One case report]. Therapie. 2014;69:521\u20134.","journal-title":"Therapie"},{"key":"17_CR21","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s10637-010-9406-6","volume":"29","author":"O Mir","year":"2011","unstructured":"Mir O, Coriat R, Gregory T, Ropert S, Billemont B, Goldwasser F. Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents. Invest New Drugs. 2011;29:716\u20138.","journal-title":"Invest New Drugs"},{"key":"17_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11936-014-0353-y","volume":"16","author":"E Standl","year":"2014","unstructured":"Standl E, Erbach M, Schnell O. Dipeptidyl-peptidase-4 inhibitors and heart failure: class effect, substance-specific effect, or chance effect? Curr Treat Options Cardiovasc Med. 2014;16:353.","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"17_CR23","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1111\/dme.12134","volume":"30","author":"Y Saisho","year":"2013","unstructured":"Saisho Y, Itoh H. Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect? Diabet Med. 2013;30:e149\u201350.","journal-title":"Diabet Med"},{"key":"17_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.4088\/JCP.12cr08283","volume":"74","author":"Y Dagan","year":"2013","unstructured":"Dagan Y, Katz G. A case of atypical antipsychotic-induced somnambulism: a class effect. J Clin Psychiatry. 2013;74:370.","journal-title":"J Clin Psychiatry"},{"key":"17_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1517\/14740338.6.4.451","volume":"6","author":"RP van Manen","year":"2007","unstructured":"van Manen RP, Fram D, DuMouchel W. Signal detection methodologies to support effective safety management. Expert Opin Drug Saf. 2007;6:451\u201364.","journal-title":"Expert Opin Drug Saf"},{"key":"17_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/gm413","volume":"5","author":"MP Schroeder","year":"2013","unstructured":"Schroeder MP, Gonzalez-Perez A, Lopez-Bigas N. Visualizing multidimensional cancer genomics data. Genome Med. 2013;5:9.","journal-title":"Genome Med"},{"key":"17_CR27","unstructured":"DailyMed [http:\/\/dailymed.nlm.nih.gov\/]"},{"key":"17_CR28","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jama.282.14.1371","volume":"282","author":"FA McAlister","year":"1999","unstructured":"McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' guides to the medical literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA. 1999;282:1371\u20137.","journal-title":"JAMA"},{"key":"17_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93:539\u201346.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Biomedical Semantics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13326-015-0017-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13326-015-0017-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13326-015-0017-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13326-015-0017-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T10:51:21Z","timestamp":1630579881000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsem.biomedcentral.com\/articles\/10.1186\/s13326-015-0017-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["17"],"URL":"https:\/\/doi.org\/10.1186\/s13326-015-0017-1","relation":{},"ISSN":["2041-1480"],"issn-type":[{"value":"2041-1480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,1]]},"assertion":[{"value":"6 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"18"}}